Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cadherin 26 is a transmembrane cell adhesion molecule belonging to the cadherin family of proteins, characterized by calcium-dependent, homophilic, and integrin-mediated cell-cell adhesion[2][3]. It is predominantly expressed in epithelial tissues, especially in the gastrointestinal tract and airway epithelium[2][4]. CDH26 mediates interactions with catenin family members (e.g., alpha-, beta-, and p120-catenin) and binds alpha integrins such as α4 and αE, facilitating epithelial barrier integrity and modulating immune cell migration and activation. CDH26 expression is heightened during allergic and inflammatory responses, and it has emerged as both a structural and immunomodulatory molecule, with potential for therapeutic targeting via fusion proteins to suppress T-helper cell activation[1][2][3]. It is implicated in diseases involving epithelial dysfunction and allergic inflammation, but therapeutic targeting in humans is still investigational.
Modulation of leukocyte adhesion and activation; Potential immunosuppressive effect through Fc fusion protein (CDH26-Fc)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cadherin 26 (CDH26).